TORONTO, June 2 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced management changes to support the commercialization of the Company's first product, ColonSentry(TM).
Effective May 31, 2008, Dr. K. Wayne Marshall has resigned as President and CEO to take on new duties as Chief Clinical Scientist for GeneNews. Dr. Marshall has also been appointed Vice Chair of the GeneNews Board of Directors. The Board has appointed a committee of three independent directors to manage the search for a new President and CEO. In the interim, Dr. Heiner Dreismann, an independent director of GeneNews and former President and CEO of Roche Molecular Diagnostics, will oversee the Company's business as Lead Director. Ms. Gailina Liew, formerly Senior Vice President, has also been appointed as acting Chief Operating Officer with responsibility for the operations of the Company.
"As GeneNews transitions into a commercial enterprise and prepares for the launch of ColonSentry, Wayne, the Board and I were in accordance that the timing was appropriate to transition leadership of the Company to a President and CEO with experience in the global commercialization of molecular diagnostics," said Mr. Rory Riggs, Chair of the Board of Directors. "In the interim, Dr. Dreismann's extensive experience and leadership at Roche Molecular Diagnostics will ensure that GeneNews is well prepared to enter the commercialization phase."
"We have worked hard to ensure that ColonSentry is the world's first blood-based test for colorectal cancer screening. I'm excited about the upcoming commercial launch of ColonSentry and committed to contributing to the future success of GeneNews in my new role as Chief Clinical Scientist and Vice Chair of the Board," added Dr. Marshall.
"I welcome the opportunity to play a leading role during this
|SOURCE GeneNews Limited|
Copyright©2008 PR Newswire.
All rights reserved